Calamos Advisors LLC Has $3.48 Million Holdings in Ascendis Pharma A/S $ASND

Key Points

• Calamos Advisors LLC boosted its position in Ascendis Pharma by 152.7% in Q4, adding 9,850 shares to hold 16,300 shares valued at approximately $3.48 million at quarter-end.
• Ascendis reported a quarterly EPS loss of $‑0.64 (missing the consensus of $‑0.06) but posted revenue of about $290.4M; the stock trades near $229 with a 52-week range of $150.89–$250.74 and a market cap around $14.3B.
• Analysts are generally positive—MarketBeat shows a consensus rating of "Moderate Buy" with an average target of about $291.56, and several firms have raised targets into the $260–$300+ range.

Calamos Advisors LLC increased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 152.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,300 shares of the biotechnology company's stock after purchasing an additional 9,850 shares during the quarter. Calamos Advisors LLC's holdings in Ascendis Pharma A/S were worth $3,476,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Rhumbline Advisers lifted its holdings in shares of Ascendis Pharma A/S by 4.0% during the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company's stock worth $249,000 after acquiring an additional 55 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Ascendis Pharma A/S by 1.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,081 shares of the biotechnology company's stock valued at $1,209,000 after acquiring an additional 58 shares during the last quarter. Farther Finance Advisors LLC raised its position in Ascendis Pharma A/S by 15.1% during the fourth quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company's stock valued at $117,000 after purchasing an additional 72 shares in the last quarter. Jones Financial Companies Lllp raised its position in Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 83 shares in the last quarter. Finally, New Wave Wealth Advisors LLC lifted its stake in Ascendis Pharma A/S by 3.7% during the fourth quarter. New Wave Wealth Advisors LLC now owns 2,518 shares of the biotechnology company's stock worth $537,000 after purchasing an additional 89 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND opened at $229.27 on Monday. Ascendis Pharma A/S has a 52-week low of $150.89 and a 52-week high of $250.74. The company has a market capitalization of $14.30 billion, a PE ratio of -52.11 and a beta of 0.49. The company has a fifty day moving average of $231.26 and a 200-day moving average of $218.01.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The company had revenue of $290.38 million during the quarter, compared to the consensus estimate of $285.35 million. On average, equities analysts forecast that Ascendis Pharma A/S will post 4.13 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on ASND. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 21st. Bank of America upped their price objective on Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a "buy" rating in a research report on Thursday, April 16th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $300.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Wedbush reiterated an "outperform" rating and issued a $273.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, April 9th. Finally, Wolfe Research reissued an "outperform" rating and set a $260.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S has an average rating of "Moderate Buy" and a consensus target price of $291.56.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.